Immunosuppressive Medicines Do Not Worsen COVID-19 Outcomes
Research Outlines Benefits of bDMARDs to Treat Early RA
Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More
FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease
Risankizumab May Improve Symptoms of PsA
Long-Term Safety of Baricitinib for RA
Tofacitinib Promising for Adults with AS
Upadacitinib Safety Similar to Other Jakinibs for RA
The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?
- 1
- 2
- 3
- …
- 21
- Next Page »